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Role of mass drug administration in elimination of 
Plasmodium falciparum malaria: a consensus modelling study
Oliver J Brady*, Hannah C Slater*, Peter Pemberton-Ross*, Edward Wenger*, Richard J Maude*, Azra C Ghani, Melissa A Penny, Jaline Gerardin, 
Lisa J White, Nakul Chitnis, Ricardo Aguas, Simon I Hay, David L Smith, Erin M Stuckey, Emelda A Okiro, Thomas A Smith, Lucy C Okell
Summary
Background Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO 
in some settings. We used consensus modelling to understand how to optimise the effects of mass drug administration 
in areas with low malaria transmission.
Methods We collaborated with researchers doing field trials to establish a standard intervention scenario and 
standard transmission setting, and we input these parameters into four previously published models. We then 
varied the number of rounds of mass drug administration, coverage, duration, timing, importation of infection, and 
pre-administration transmission levels. The outcome of interest was the percentage reduction in annual mean 
prevalence of P falciparum parasite rate as measured by PCR in the third year after the final round of mass drug 
administration.
Findings The models predicted differing magnitude of the effects of mass drug administration, but consensus 
answers were reached for several factors. Mass drug administration was predicted to reduce transmission over a 
longer timescale than accounted for by the prophylactic effect alone. Percentage reduction in transmission was 
predicted to be higher and last longer at lower baseline transmission levels. Reduction in transmission resulting from 
mass drug administration was predicted to be temporary, and in the absence of scale-up of other interventions, such 
as vector control, transmission would return to pre-administration levels. The proportion of the population treated in 
a year was a key determinant of simulated effectiveness, irrespective of whether people are treated through high 
coverage in a single round or new individuals are reached by implementation of several rounds. Mass drug 
administration was predicted to be more effective if continued over 2 years rather than 1 year, and if done at the time 
of year when transmission is lowest.
Interpretation Mass drug administration has the potential to reduce transmission for a limited time, but is not an 
effective replacement for existing vector control. Unless elimination is achieved, mass drug administration has to be 
repeated regularly for sustained effect.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Despite the gains made towards elimination of 
Plasmodium falciparum malaria in the past 15 years, many 
countries still have endemic transmission1 and are 
increasingly looking to new strategies to accelerate 
progress. Mass drug administration (MDA) involves the 
time-limited distribution of drugs to a target population, 
irrespective of infection status. It has been used only 
sporadically against malaria in most settings, and cluster-
randomised trials, the most robust studies of the effect of 
MDA on transmission, are few.2,3 However, MDA has 
received renewed interest as a strategy to clear chronic 
asymptomatic infections (NCT01872702) and rapidly 
reduce transmission.4,5
In September, 2015, WHO’s Malaria Policy Advisory 
Committee recommended for the first time the use of 
MDA in specific circumstances: when transmission is 
close to being interrupted, vector control, effective 
surveillance, and access to case management are at high 
coverage, and importation of infection is minimal; as a 
component of accelerated elimination in areas of the 
Greater Mekong Subregion, which are under threat of 
multidrug resistance; or for malaria epidemics or during 
complex emergencies.6 National malaria control 
programmes and partners need to decide what role, if 
any, MDA should have in control and elimination 
strategies. To answer this question, the best operational 
strategies for MDA and how best to combine MDA with 
other interventions need to be established.
To help with the Malaria Policy Advisory Committee’s 
decision making, an evidence review group was 
established to synthesise available evidence for the effect 
of MDA on transmission of malaria.7 This synthesis 
included a few prospective field trials, retrospective 
analyses of previous MDAs, and a mathematical-model 
comparison analysis. Mathematical models are a useful 
way of assessing the knowledge accumulated from field 
trials of MDA and predicting how effectiveness might 
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vary in settings where MDA has not yet been tested. The 
Malaria Modelling Consortium was tasked to compare 
findings from four established models (OpenMalaria,8 
EMOD Disease Transmission Kernel [DTK],9 Imperial,10,11 
and Mahidol Oxford Tropical Medicine Research Unit 
(MORU]12,13) on the effectiveness of MDA in different 
settings. Model development involves deciding on model 
structure, parameters, and assumptions, validation 
against epidemiological data, and assessment of 
uncertainties at each stage of this process.
We report the results of the Malaria Modelling 
Consortium’s MDA model comparison and their 
implications for the utility of MDA. Our aim for this 
analysis is to help with decisions on the relative 
prioritisation of MDA within wider malaria-control 
strategies.
Methods
Malaria-control programmes implementing MDA need 
to decide on several operational factors, including the 
number of rounds, timing, and frequency of treatment. 
Furthermore, the effect of MDA can be influenced by 
epidemiological factors in each setting, such as malaria 
transmission level and infection importation rates. The 
Malaria Modelling Consortium collaborated with 
partners doing field trials of MDA to identify probable 
scenarios for MDA deployment and common operational 
choices that would need to be made within realistic 
logistic constraints.
First, a standard MDA intervention scenario was defined 
to use as a basis for comparison (table 1). This scenario 
consisted of two rounds of treatment per year, 5 weeks 
apart, with a standard regimen of dihydroartemisinin–
piperaquine at 70% effective coverage, for 2 years. A 
standard setting was chosen (table 1), specifying 5% slide 
P falciparum parasite rate in 2–10-year-olds (PfPR2–10) before 
MDA, intermediate seasonal variation in transmission 
with one rainy season, and no importation of infection. In 
further simulations, we varied operational factors that are 
of primary interest because they can be adjusted in an 
MDA programme: the number of rounds per year, the 
effective coverage of each round, the interval between 
rounds, and the duration of the MDA programme. Each 
model was used to do a multivariate analysis that simulated 
the baseline conditions with every combination of the 
selected parameters (table 1), producing 48 different MDA 
programmes. We also tested how the effect of MDA could 
vary depending on the local setting with respect to seasonal 
timing, vector control, importation of infection, and drug 
resistance; these analyses were done in selected models 
according to which were most appropriate for each setting. 
The outcome metric was the percentage reduction in 
annual mean all-age prevalence of P falciparum as 
measured by PCR (PfPRPCR) in the third year after the 
final round of MDA. The models assessed represent four 
different ways of simulating malaria transmission and 
MDA, and a summary of their characteristics and 
functionality is given in table 2.11,14–29
Research in context
Evidence before this study
We did not do a search of published work, because three 
comprehensive reviews have been published in the past 4 years. A 
Cochrane review done in 2013 found two cluster-randomised 
trials, eight non-randomised controlled studies, and 
22 uncontrolled before–after studies of mass drug administration. 
Most studies showed a substantial initial effect on parasitaemia. 
However, there was little evidence for effects beyond 6 months. 
Two further comprehensive reviews published in 2015 had wider 
inclusion criteria, and included published and unpublished work 
and studies not yet published. These reviews showed that mass 
drug administration was implicated in local elimination of 
malaria in some settings, particularly remote areas with small 
populations and low initial malaria transmission, but not in areas 
of higher transmission. Mass drug administration has been 
simulated in several mathematical modelling studies but, as in 
field studies, many factors—such as the number of doses given, 
number of rounds of treatment, choice of drugs, local malaria 
transmission intensity, and outcomes of interest—have varied 
greatly, all of which are likely to affect outcomes.
Added value of this study
In this study, a consortium of modelling groups investigated 
the degree of consensus of four established malaria 
transmission models in terms of the main determinants of the 
effect of mass drug administration and how large an effect on 
prevalence is likely to be achieved. In consultation with 
partners who are doing field trials of mass drug 
administration, we chose various programme options 
(eg, number of rounds, choice of drug) that were considered 
logistically feasible. We standardised many inputs and outputs 
of the models, such as initial slide prevalence, outcomes of 
interest, and implementation options. Our analysis 
showed—despite many differences in assumptions between 
the four models, for example about the underlying 
transmission dynamics of malaria—broad consensus between 
the models on how mass drug administration should be 
implemented to optimise effects, and the settings in which 
such programmes will be most effective.
Implications of all the available evidence
High coverage in the target population and mass drug 
administration in more than 1 year are important to maximise 
reductions in transmission. Reductions in transmission last 
longest in low-transmission settings but, unless elimination 
and prevention of reintroduction are achieved, malaria 
transmission will return to pre-intervention levels after the 
programme of mass drug administration finishes.
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Role of the funding source
EMS and EAO are or have been employed by the study 
funder, and were involved in data collection, analysis, 
and interpretation, and writing of the Article. However, 
they were not involved in study design The funder had 
no further role in study design; data collection, analysis, 
or interpretation; or writing of the Article. The 
corresponding author had access to all study data and 
was responsible for the final decision to submit for 
publication.
Results
In all four models, simulated prevalence fell substantially 
immediately after MDA (figure 1) as a result of successful 
clearance of infection and the prophylactic effect of 
piperaquine, a long-acting artemisinin-combination 
therapy partner drug. However, in the absence of 
elimination, the models predicted that prevalence of 
infection would thereafter return to pre-intervention 
levels (at different rates in different models). After the 
prophylactic effect of the partner drug has declined, the 
key factors that determine local transmission intensity, 
such as the density of mosquitoes, have not been 
permanently changed. Thus, without some other long-
term intervention, such as improved vector control, the 
effects of MDA were predicted to be transient.
Although the four different models showed similar 
trends in the effects of MDA with time, substantial 
differences were noted in both simulated pre-intervention 
transmission and the magnitude of the effect (figures 1, 2). 
Pre-intervention PfPRPCR differed between models 
because we standardised these initial conditions to 
5% slide prevalence in 2–10-year-olds, and the models 
make several different assumptions, for example about 
the relation between slide and PCR prevalence. The 
EMOD DTK and MORU models predicted a reduction in 
PfPRPCR of 64% in the third year after MDA, OpenMalaria 
a reduction of 58%, and Imperial a reduction of 19%. 
These differences were caused by many different 
assumptions, including the relation between 
entomological inoculation rate, prevalence, and the basic 
case reproduction number (R0); the effect of case 
management; the degree of stochastic variability; and the 
dynamics of immunity.
Despite the differences in effect size predicted by the 
different models, there was generally greater agreement 
as to the relative effect of different operational choices. 
Effective coverage had a large effect on percentage 
reduction in PfPRPCR in all models. For example, the 
median percentage reduction in PfPRPCR in the standard 
scenario at 30% coverage was 15% (range across models 
10–30); at 70% coverage, it was 61% (range 19–64; 
figure 2). Duration of intervention was also important in 
all models, with prevalence estimated to remain low for 
longer with 2 years of MDA than with 1 year of MDA 
(figure 2). When multiple rounds of MDA are done, all 
models showed that coverage overlap substantially affects 
MDA. For example, if participation was entirely random 
in each round, two rounds of MDA at 70% coverage 
would reach roughly 90% of the population with one or 
more treatment courses. However, if the same individuals 
participated in each round, then two rounds at 
70% coverage would reach only 70% of the population. In 
reality, the situation is likely to be somewhere between 
the two extremes, and strategies that specifically target 
individuals missed in the first round are likely to be more 
effective as long as these strategies do not come at the 
expense of maximising the total number of individuals 
treated per year.
All four models suggested that, with closely spaced 
rounds of MDA (ie, intervals of 4–6 weeks), the most 
important operational factor determining effect is the 
proportion of the population who do not receive any 
treatment in any round (figure 3). Implementation of three 
rather than two rounds of treatment per year had negligible 
effects if the same individuals participated in each round at 
intervals of 4–6 weeks, but resulted in better outcomes if 
Standard scenario value Values when varied
Programmatic considerations
Rounds of mass drug 
administration per year
2 3
Effective coverage* (%) 70% 30%, 50%, 90%
Coverage correlation between 
rounds
1† or 0‡ 0 or 1
Interval between rounds 5 weeks 4 weeks, 6 weeks
Duration of programme 2 years 1 year
Time of year when mass drug 
administration begins
Optimum (as defined by each 
group) in a Zambia-like seasonality
Each month of the year
Other interventions Insecticide-treated bednets at 
80% effective coverage and access 
to passive treatment with 
artemisinin-based combination 
therapy at 60% throughout the 
simulation
Removal of vector control, 
simulated by a ten-fold increase in 
the emergence rate of adult 
mosquitos starting at the beginning 
of the year in which mass drug 
administrated is implemented
Choice of drug Long-lasting artemisinin-based 
combination therapy with 
properties similar to 
dihydroartemisinin–piperaquine
··
Transmission setting characteristics
Baseline transmission intensity 5% PfPR2–10, as measured by 
microscopy
1 to 10
Importation of malaria cases None 0·4–1·6 infections per 
10 000 people per year14
Population size 10 000 1000
Artemisinin resistance 0% Variable
Seasonality profile Zambia-based single annual rainy 
season profile
Two rainy seasons per year, no 
seasonal variation in transmission
The standard intervention scenario was used as a basis for comparison and values were varied as shown. 
PfPR2–10=Plasmodium falciparum parasite rate in children aged 2–10 years. *Defined as the percentage of the population 
that takes the full course of drug that clears all parasites (the product of access to intervention, adherence, and drug 
efficacy). The denominator corresponds to the entire population; ineligible people (eg, pregnant women) and infants 
younger than 6 months are not included in mass drug administrations. †The same people are treated in each round in 
the EMOD Disease Transmission Kernel, Imperial, and OpenMalaria models. ‡Random individuals are treated in each 
round in the Mahidol Oxford Tropical Medicine Research Unit model.
Table 1: Model input parameters for programme options and local settings for mass drug administration
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EMOD DTK Imperial MORU OpenMalaria
Institutional home Institute for Disease Modelling Imperial College London Mahidol Oxford Tropical 
Medicine Research Unit
Swiss Tropical and Public Health 
Institute
Type of model and 
references
Individual-based stochastic 
microsimulation16, 17
Individual-based stochastic 
microsimulations of malaria in 
human beings linked to a 
stochastic compartmental model 
for mosquitoes11
Deterministic compartmental 
model described by 
differential equations,18 
including drug action on each 
stage of the infection
Single-location individual-based 
simulation of malaria in human 
beings14 linked to deterministic 
model of malaria in 
mosquitoes19
How infections are 
tracked
Tracks parasite densities of 
different surface-antigen types
Tracks membership of categories 
of infection (symptomatic, 
asymptomatic, submicroscopic, 
treated)
Tracks membership of 
categories of infection
Tracks parasite densities 
corresponding to different 
infection events
Relationship between 
entomological 
innoculation rate and 
prevalence
Immunity is acquired through 
cumulative exposure to 
different antigenic 
determinants,20 with 
heterogeneity in individual 
biting rates included
Immunity is acquired through 
cumulative exposure to 
mosquito bites, with 
heterogeneity in individual biting 
rates included
Subdivides population into 
non-immune and immune 
classes
Submodels of infection of 
human beings14 and of 
blood-stage parasite densities, 
with main immune effects 
controlling parasite densities21
Duration of infections Infection duration based 
on malaria therapy20 and 
cross-sectional survey data22
Infection duration based on 
fitting to asexual parasite 
prevalence data by age, 
transmission intensity, 
seasonality
Infection duration based on 
malaria therapy data and data 
from endemic areas
Infection duration based on 
malaria therapy data21
Effect of mass drug 
administration or case 
management
Reduces blood-stage parasite 
densities according to age-
specific and dose-specific 
pharmacokinetics and 
pharmacodynamics,22 with 
corresponding clearance and 
prophylactic effects
Truncates infections and has 
subsequent prophylactic effect 
based on fitting pharmacokinetic 
and pharmacodynamic models 
to field studies
Post-treatment prophylactic 
period derived from field 
studies of time to next 
infection
Truncates infections, and has 
subsequent prophylactic effect 
based on pharmacokinetic and 
pharmacodynamic studies
Validation against 
trials of mass drug 
administration or 
mass screening and 
treatment
Assessed against MACEPA trial 
of mass screening and 
treatment in southern 
Zambia23
Assessed against a controlled 
trial24 of mass drug 
administration in Burkina Faso 
(model slightly optimistic about 
effect vs data), and the MACEPA 
trial of mass screening and 
treatment in southern Zambia 
(model matched data)
Fitted to a trial of mass drug 
administration in Cambodia25
Fitted to the data of the Garki 
project (Matsari),26 and assessed 
against the MACEPA trial of 
mass screening and treatment 
in southern Zambia27
Infectiousness to 
mosquitoes
A function of mature 
gametocyte and cytokine 
densities20,22
Related to asexual parasite 
dynamics and lagged to allow for 
development of gametocytes
Infected individuals have a 
constant infectiousness
Lagged function of asexual 
parasite density28
Heterogeneity in 
exposure
Age-dependent biting29 and 
configurable distribution of 
household variability (the 
latter disabled in this analysis)
Included Not included Included
Initial state ·· Back-calculating required 
mosquito density to achieve 
given initial prevalence at an 
approximate steady state in the 
presence of treatment and long-
lasting insecticide-treated nets
Set transmission rate to 
achieve given initial 
prevalence at an approximate 
steady state in the presence 
of treatment
Back-calculating required 
mosquito density to achieve 
given initial prevalence at an 
approximate steady state in the 
presence of treatment
Source of seasonality 
pattern
Rainfall and imputed 
temperature29 driving larval 
habitat model fitted to clinical 
incidence patterns in 
Sinazongwe and Gwembe 
districts, Zambia
Rainfall data from Zambia 
combined with larval and adult 
mosquito model
Same entomological 
innoculation rate input as 
Imperial model
Based on pattern for southern 
Zambia29
Age-structured model Yes Yes No Yes
Simulation of 
correlated rounds of 
intervention
Yes Yes No Yes
All the models are extensible to include other functionality (eg, different drugs, effects of drug resistance, effect on drug resistance, vector bionomics and details of vector 
control, different initial conditions, other concomitant interventions). A detailed comparison of EMOD DTK, Imperial, and OpenMalaria, including references to the data to 
which they are fitted, is available elsewhere.15  DTK=Disease Transmission Kernel. MORU=Mahidol Oxford Tropical Medicine Research Unit. MACEPA=Malaria Control and 
Elimination Partnership in Africa.
Table 2: Summary of models of malaria transmission
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additional people were reached in the third round who had 
not previously received treatment that year. Spacing 
within-year MDA rounds 4 weeks apart rather than 6 weeks 
apart made little difference in terms of overall effects.
In settings with one rainy season a year, all models 
predicted greater reductions in PfPRPCR if MDA was done 
during the dry season or at the end of the rainy season, as 
previously found in similar analyses by the separate 
models.12,13,30–32 In the Imperial model, reductions in 
PfPRPCR were as much as 1·45 times greater if MDA was 
done in the dry season or at the end of the rainy season 
than at the beginning of the rainy season. Seasonal 
timing has less of an effect on PfPRPCR in the OpenMalaria 
and MORU models. In a setting with two rainy seasons 
per year, we predicted that timing of MDA had less of an 
effect, because transmission was more evenly spread 
throughout the year. At a given mean baseline slide 
prevalence, MDA was predicted to be marginally more 
effective in a seasonal setting (at the optimum time) than 
in a non-seasonal setting.
The introduction of MDA while vector control was 
simultaneously removed led to a sudden and large 
increase in simulated all-age prevalence, and the 
subsequent MDA programme did very little to reduce 
this shift even in the short term (OpenMalaria and 
Imperial models). We predicted, therefore, that an MDA 
programme of this type is insufficient to replace vector 
control, even at the highest levels of coverage.33
In a high prevalence setting (ie, 10% PfPR2–10), the 
percentage reduction in PfPRPCR was considerably lower 
in all the models compared with that in a setting with 
5% prevalence. We predicted that, even with high 
coverage (90%), three rounds per year, and 2 years of 
intervention, PfPRPCR 3 years later would be reduced by 
only a median of 48% (range across models 19–95) from 
its pre-intervention level, compared with 80% (range 
across models 56–100) in the setting with 5% baseline 
prevalence. This disparity is because transmission 
rebounds more rapidly in a higher transmission area. 
However, the absolute reduction in transmission is 
greater in higher prevalence settings because more 
infections are cleared.
When PfPR2–10 is 5%, cases imported at a low rate (as in 
the WHO-recommended MDA use scenarios), based on 
data from Zanzibar,34 represent a very small proportion of 
the total infections in the population, and therefore make 
little difference to MDA effectiveness. However, when 
PfPR2–10 is lower, imported cases would be instrumental to 
increasing transmission. MDA more easily caused 
stochastic extinction in smaller than in bigger simulated 
populations in all the models. Finally, some evidence 
(only tested with the MORU model) suggested that MDA 
with artemisinin-combination therapies could speed up 
the selection of artemisinin-resistant parasite strains 
(figure 4). However, the size of this effect could be limited 
by the high selection pressure already imposed from 
management of symptomatic cases.
Discussion
Although individual models predicted different 
magnitudes of the effects of MDA, we found substantial 
consensus on which factors have the greatest influence 
on these effects, including both the characteristics of the 
programme and the setting in which MDA is applied. 
Percentage reductions were predicted to be highest in 
low-transmission settings and smaller populations, but 
were more transient in other settings, in line with 
evidence from field studies.2,3 Infection importation rates 
(when transmission is not very low) and the spacing 
between rounds (within the 4–6 week range examined) 
had little effect. The proportion of the population reached 
by at least one round of MDA per year and the duration 
of the programme had a large influence on effectiveness, 
and our analysis suggested that these factors should be 
the focus of operational efforts.
Figure 1: Sample simulated output from four different models of effect of mass drug administration on 
all-age PCR prevalence of Plasmodium falciparum infection
From year –1 to year 0, the models are at equilibrium. The timing of each round of mass drug administration in 
each model is shown by coloured arrows. The four different models show the output under the standard 
intervention scenario (70% coverage, 2 years of mass drug administration, two rounds per year, 5 weeks between 
rounds, seasonal transmission [based on Zambia], and 5% mean annual prevalence pre-intervention by microscopy 
in 2–10-year-olds). DTK=Disease Transmission Kernel. MORU=Mahidol Oxford Tropical Medicine Research Unit.
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third year after mass drug administration
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We did not formally analyse which differences between 
the models created the variation in predicted effects of 
MDA. MDA can substantially affect transmission in the 
short term, leading to different transmission dynamics 
from those analysed in in-depth comparisons of models 
of the effects of RTS,S.15 Differences between the models 
in basic epidemiological quantities, including duration 
of untreated infections and clinical immunity, could 
be  relevant. Different levels of within-population 
heterogeneity in malaria exposure are assumed, which 
are crucial for the stability of transmission in low-
prevalence settings. Seasonal variation makes 
transmission less stable at a given prevalence, whereas 
spatial heterogeneity can make transmission more 
stable. We did not include spatial heterogeneity in 
transmission levels, but it is likely to be crucial at very 
low transmission levels. Simulations of small 
subpopulations with 5–10% prevalence, diluted by other 
subpopulations of unexposed individuals, might be 
appropriate representations of large populations with 
1% average prevalence. The size of such subpopulations 
and their degree of interconnection could then be crucial, 
because stochastic extinction is much more likely in 
smaller than in larger populations. Consideration of 
spatial structure in the models will be crucial for more 
realistic modelling of malaria elimination. In each 
model, the initial prevalence for simulations was fixed, 
but this value could correspond to very different 
epidemiological patterns, for example, of the immune 
status of human beings or vectorial capacity.
A key next step for the modelling groups is to continue 
using data from forthcoming trials of MDA to further 
validate the models and to continue efforts to understand 
how and why model predictions differ, such as under the 
HIV, tuberculosis, and neglected tropical diseases model 
consortiums.35,36 Use of modelling to understand the 
potential role of MDA in containing outbreaks after 
elimination, and to compare the predicted effects of 
MDA on drug resistance, will also be important.
The value of our simulations is that they show that, 
despite many differences in assumptions, there is a 
consensus between models on the relative influence of 
MDA operational characteristics. Many of our results 
accord with findings from MDA for lymphatic filariasis,37–39 
although caution should be taken in extrapolating 
findings between the diseases in view of the generally 
much higher reproductive number and shorter generation 
time of malaria. Our results form one part of a broad 
evidence base, including growing evidence from malaria 
field trials, which should be considered when policy 
Figure 3: Overlap in coverage between rounds of mass drug administration 
and effect on PfPRPCR
(A) shows the proportion of the population receiving one or more treatment 
courses after two rounds of mass drug administration, each at 70% coverage, 
with either random participation or the same individuals participating each time. 
(B) shows the percentage reduction in PfPRPCR 3 years after mass drug 
administration according to the proportion of the population not receiving 
treatment in any rounds in the baseline scenario. Blue triangles represent two 
rounds of mass drug administration randomly targeted at 30%, 50%, 70%, and 
90% coverage; red dots represent the same two rounds of mass drug 
administration in which the same individuals are treated in each round. Results 
shown are from the OpenMalaria model. PfPRPCR=Plasmodium falciparum parasite 
rate as measured by PCR.
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Figure 4: Effect of MDA with artemisinin-combination therapy on malaria 
prevalence and the percentage of parasites that are artemisinin resistant
Results shown are from the MORU model. Blue lines show parasite prevalence, 
whereas red lines show the percentage artemisinin resistant. Coverage was 
70% per round. MDA=mass drug administration. MORU=Mahidol Oxford 
Tropical Medicine Research Unit.
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makers decide whether MDA is a useful strategy for their 
settings. This reassessment should balance the predicted 
benefits of MDA against equivalent investments in 
existing interventions, while considering other 
consequences such as the risk of spreading resistance. 
Under no circumstances did any of the models predict 
that MDA is an effective replacement for vector control, 
and indeed the overarching message from this model 
comparison is that, without some other sustained change, 
such as improved vector control, the effects of MDA are 
likely to be transient. When MDA is implemented, 
sustainability of the programme and maintenance of 
other interventions will be major challenges to ensure 
long-term reduction in malaria burden.
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